A preclinical study offers a foundation for a combination strategy in future clinical trials for KRAS mutations.
Penn Medicine
Advertisement
Articles by Penn Medicine
In pilot study, patients saved over an hour of time at every treatment visit.
Advertisement
Latest Updated Articles
Immunotherapy May Boost KRAS-Targeted Therapy in Pancreatic CancerPublished: March 19th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5